Evaluation of proactive therapeutic drug monitoring application in infliximab users in ulcerative colitis
J. coloproctol. (Rio J., Impr.)
;
43(4): 286-291, Oct.-Dec. 2023. tab
Article
Dans Anglais
| LILACS
| ID: biblio-1528937
ABSTRACT
Objective:
To evaluate the application of proactive pro-drug therapy (TDM) at week six in users of infliximab therapy in ulcerative colitis patients and to analyze the need for further disease optimization.Method:
This is a retrospective analysis that will be carried out simultaneously at the Hospital de Clínicas de Passo Fundo and at the Endoclin Diagnostic Center in the city of Passo Fundo, with secondary data collection between January 2020 and May 2022. The sample included patients from both sexes, regardless of age, who are being followed up in the services mentioned above, by signing the informed Free and Clarified Consent Term.Results:
63.2% of patients required optimization of their treatment based on the serum level assessment at week six.Conclusion:
Proactive TDM performed at week six benefits patients in order to complete indications for treatment to avoid lack of drug response and complications from the disease. (AU)
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Rectocolite hémorragique
/
Surveillance des médicaments
Limites du sujet:
Adulte
/
Adulte très âgé
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
J. coloproctol. (Rio J., Impr.)
Thème du journal:
Cirurgia
/
Doenas Retais
/
Doenas do Colo
/
Gastroentérologie
/
Cirurgia
Année:
2023
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Endoclin Diagnostic Center/BR
/
Hospital de Clínicas de Passo Fundo/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS